AMINOSYN II 8.5% W/ ELECTROLYTES Drug Patent Profile

When do Aminosyn Ii 8.5% W/ Electrolytes patents expire, and what generic alternatives are available?

Aminosyn Ii 8.5% W/ Electrolytes is a drug marketed by Icu Medical Inc and is included in one NDA.

The generic ingredient in AMINOSYN II 8.5% W/ ELECTROLYTES is amino acids; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride. There are three hundred and fifty drug master file entries for this compound. Additional details are available on the amino acids; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride profile page.

Summary for AMINOSYN II 8.5% W/ ELECTROLYTES

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AMINOSYN II 8.5% W/ ELECTROLYTES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Icu Medical Inc	AMINOSYN II 8.5% W/ ELECTROLYTES	amino acids; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride	INJECTABLE;INJECTION	019437-005	Apr 3, 1986		DISCN	No	No

Summary
Aminosyn II 8.5% with Electrolytes is a parenteral nutrition (PN) product used in hospitals for patients unable to ingest or absorb nutrients orally. Its investment profile depends on market demand, patent status, manufacturing complexity, competitive landscape, and regulatory environment. Currently, the product is off-patent, with broad competition among generic manufacturers. Future growth hinges on hospital utilization, clinical guidelines, and the ability of key players to maintain supply and quality standards.

---

What Is the Market and Demand for Aminosyn II with Electrolytes?
Aminosyn II is part of the intravenous (IV) amino acid therapies segment, primarily used in hospital settings for nutritional support. The overall parenteral nutrition market was valued at approximately $4.2 billion globally in 2022. It is expected to grow at a compound annual growth rate (CAGR) of 6% to 8% through 2027, driven by rising incidence of malnutrition among hospitalized patients and expanded use in critical care.

Hospital use accounts for roughly 70% of the demand, with the remainder supplied to specialized clinics. Growth factors include increased awareness of nutritional support, aging populations, and expanding use in oncology and post-surgical care. The product’s utilization is sensitive to clinical guidelines, approval of alternative formulations, and hospital budget constraints.

Key demand influencers:

Last updated: February 4, 2026

• Aging population and chronic illnesses increase the need for nutritional support.
• COVID-19 has temporarily boosted demand in critical care settings.
• Hospital procurement strategies and formulary decisions impact product volume.

---

What Is the Competitive Landscape and Manufacturing Complexity?
Aminosyn II 8.5% USP with Electrolytes is produced by several generic drug companies. Its patent expiry occurred around 2010, leading to widespread generic competition. Major players include Hospira, Fresenius Kabi, Baxter, and Hikma Pharmaceuticals, among others.

Manufacturing of amino acid solutions involves complex sterile processing facilities, quality control, and stringent regulatory oversight (FDA, EU, other health authorities). Entry barriers are high due to the need for specialized equipment, good manufacturing practices (GMP), and supplier qualification.

Market share is fragmented. No single entity dominates, but second-generation products and branded offerings attempt to differentiate through formulation variations or added nutrients. Price competition is intense, driven by hospital purchasing groups and bulk procurement.

Pricing dynamics:

• Average wholesale price (AWP) for Aminosyn II — Approx. $7 to $10 per 100 mL.
• Contract pricing with hospitals can be significantly lower, affecting margins.
• Price erosion is ongoing due to increased competition and tendering.

---

What Is the Regulatory Environment and Patent Status?
Post-patent expiry, the product relies on regulatory approvals and compliance. No patent protection exists currently, easing generic entry. Regulatory hurdles primarily concern manufacturing standards, labeling, and quality assurance.

New formulations or combination products require clinical and stability data for approval, but standard amino acid solutions face minimal regulatory delay once established. The main risk lies in supply chain disruptions, regulatory non-compliance, or changes to clinical guidelines that favor alternative nutritional strategies.

---

What Are the Key Risks and Opportunities?
Risks:

• Market saturation with generic equivalents limits pricing power.
• Hospital budget focus pushes for cost-effective solutions, pressuring margins.
• Shifts toward alternative nutrition methods could reduce reliance.
• Regulatory changes influencing hospital procurement policies.

Opportunities:

• Increasing demand from aging and chronically ill populations.
• Potential growth in emerging markets with expanding healthcare infrastructure.
• Implementation of protocols favoring amino acid solutions in specific clinical indications.

Emerging trends:

• Customized amino acid formulations to meet specific patient needs.
• Integration into comprehensive parenteral nutrition protocols targeting ICU patients.
• Technological advances that improve manufacturing efficiency or stability.

---

Financial and Investment Considerations
Given its status as a commodity product with broad generic competition, the direct investment value in Aminosyn II typically lies in companies with established market share and manufacturing capacity. Its profitability is mainly driven by volume, with margins under pressure due to pricing competition.

Investors should evaluate:

• Company market share and ability to sustain supply levels.
• Cost control and manufacturing efficiencies.
• Hospital procurement contracts and tender success.
• Regulatory compliance and risk management strategies.

As a standalone asset, it offers stable but not explosive growth prospects. Its value is more suitable as part of a diversified portfolio of hospital-essential generics.

---

Key Takeaways

• Aminosyn II 8.5% with Electrolytes is a mature, off-patent IV amino acid product competing primarily on pricing and supply stability.
• The global parenteral nutrition market is growing, driven by aging and chronically ill populations, with hospital demand remaining the primary driver.
• Market share is fragmented among numerous generic manufacturers facing price compression.
• Manufacturing complexity is moderate-to-high due to sterile processing requirements, but entry barriers are significant post-patent expiry.
• Clinical, regulatory, and economic factors influence hospital utilization and procurement, affecting long-term demand and profitability.

---

FAQs

1. How does patent expiry affect the investment outlook for Aminosyn II?
Patent expiry leads to increased generic competition, reducing pricing power and profit margins. Long-term stability depends on manufacturing efficiency, supply chain reliability, and hospital adoption rates. No current patent protection limits the potential for exclusive control.

2. What are the main competitive advantages for manufacturers of Aminosyn II?
Manufacturers with efficient production facilities, established relationships with hospital procurement systems, and consistent regulatory compliance can maintain or grow market share despite intense price competition.

3. How sensitive is demand for Aminosyn II to clinical guidelines?
Demand shifts if clinical guidelines favor alternative formulations or route of administration, such as tailored amino acid mixtures or total parenteral nutrition protocols that exclude standard solutions.

4. What role do emerging markets play in the future of Aminosyn II?
Emerging markets with expanding healthcare infrastructure, increased hospital capacity, and rising disease burden provide growth opportunities, though price sensitivity remains a concern.

5. What risks are associated with supply chain disruptions?
Interruptions in raw material procurement, manufacturing, or distribution can reduce hospital availability, impacting revenue and reputation. Regulatory non-compliance can lead to product recalls or bans, further affecting supply stability.

---

References
[1] MarketResearch.com, "Global Parenteral Nutrition Market," 2022.
[2] EvaluatePharma, "Hospital and Parenteral Nutrition Industry Data," 2022.
[3] U.S. FDA, "Guidance for Industry: Parenteral Nutrition," 2021.
[4] IQVIA, "Pharmaceutical Pricing and Market Dynamics," 2022.
[5] Statements from major manufacturers' financial reports and market analysis documents (Hospira, Fresenius Kabi, Baxter, Hikma).